Slight difference in primary amino acid sequence of p17 matrix protein of HIV-1 exerts profound influence on its antigenicity

Archives of Virology

Volumn 143, Issue 5, 1998, Pages 881-890

  Taniguchi, K ^a,b   Tsuchie, H ^a   Kageyama, S ^c   Iwasaki, M ^a,b   Takagi, T ^a   Sasao, F ^a   Ueda, S ^a   Kurimura, T ^a  

^a OSAKA UNIVERSITY   (Japan)

^b EIKEN CHEMICAL CO LTD   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ANTIGEN STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; MONOCLONAL ANTIBODY; VIRUS INFECTIVITY; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; VIRAL PROTEINS; VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031807245     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050050339     Document Type: Article

References (36)

1. Myers G, Hahn BH, Mellors JW, Henderson LE, Korber B, Jeang KT, McCutchan FE, Pavalakis GN (1995) Human retrovirus and AIDS. Los Alamos National Laboratory, Los Alamos
2. Gelderblom H R (1991) Assembly and morphogenesis of HIV: potential effect of structure on viral function. AIDS 5: 617-638
3. Bryant M, Ratner L (1990) Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 87: 523-527
4. Yuan X, Yu X, Lee T-H, Essex M (1993) Mutations in N-terminal region of human immunodeficiency type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 67: 6387-6394
5. Nermut MV, Hockley DJ, Jowett JBM, Jones IA, Garreau M, Thomas D (1994) Fullerence-like organization of HIV gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology 198: 288-296
6. Lodge R, Gottlinger H, Gabuzda D, Cohen EA, Lemay G (1994) The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type I in MDCK cells. J Virol 68: 4857-4861
7. Yu X, Yu Q-C, Lee T-H, Essex M (1992) The C terminus of human immunodeficiency virus type I matrix protein is involved in the early steps of the virus life cycle. J Virol 66: 5667-5670
8. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M (1993) Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type I with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 90: 6125-6129
9. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, Stevenson M (1996) Phosphorylation-depandent human immunodeficiency virus type 1 infection and nuclear targeting of virual DNA. Proc Natl Acad Sci USA 93: 367-371
10. Allan JS, Coligan JE, Barin F, Sodroski J, Rosen CA, Haseltine WA, Lee T-H, Essex M (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091-1094
11. Lange J, de Wolf F, Krone W, Danner S, Coutinho R, Goudsmit J (1987) Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS 1: 155-159
12. Kageyama S, Kurimura T (1990) Disappearance of anti-p17 correlates with successful isolation of human immunodeficiency virus and deterioration in clinical status. Int J STD AIDS 1:129-131
13. Choudhury AM, Yamada O, Wakamiya N, Kurimura T, (1992) A prospective study on correlation between the decrease in anti-p17 antibody level and progression to AIDS in asymptomatic carriers of HIV. Microbiol Immunol 36: 883-840
14. Naylor PH, Naylor CW, Badamchian M, Wada S, Goldstein AL, Wang SS, Sun DK, Thornton AH, Sarin PS (1987) Human immunodeficiency virus contains an epitope immunoreactive with thymosin α 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc Natl Acad Sci USA 84: 2951-2955
15. Kahn J, Stiles D, Scillian J, Murcar N, Stryker R, Volberding P, Naylor P, Goldstein A, Sarin P, Simmon V, Wang SS, Haseltine P (1992) A phase I study of HGP-30, a amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects. AIDS Res Hum Retroviruses 8: 1321-1325
16. Papsidero LD, Sheu M, Ruscetti FW (1985) Human immunodeficiency virus type 1 neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol 63: 267-272
17. Shang F, Huang H, Revensz K, Chen HC, Herz R, Pinter A (1991) Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein p17: identification of epitope exposed at the surfaces of infected cells. J Virol 65: 4798-4804
18. Sarin PS, Mora CA, Naylor PH, Markham R, Schwanz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, Goldstein AL (1995) HIV-I p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol 41: 401-407
19. Kageyama S, Katsumoto T, Taniguchi K, Ismail SI, Simmen T, Sasao F, Gao M, Owatari S, Wakamiya N, Tsuchie H, Ueda S, Shiraki K, Kurimura T (1996) Neutralization of human immunodeficiency virus with anti-p17 from carrier's plasma. Acta Virol 40: 195-200
20. Saitoh A, Tanaka N, Nakata K, Ikuta K, Shinagawa H (1992) A unique monoclonal antibody that recognizes mature p17 of HIV-I but not its precursor. Microbiol Immunol 36: 105-110
21. Gathuru JH, Miyoshi I, Naiki M (1987) Electrically stimulated fusion of human UC 729-6 cell line potentially useful for generating antibody secreting human-human hybridomas. Jpn J Vet Res 35: 109-113
22. Ishikawa E, Hashida S, Yoshitake S, Hamaguchi Y, Ueno T (1983) Enzyme-labeling of antibodies and immunoassay and immunohistochemical staining. J Immunoassay 4: 209-327
23. Tsuchie H, Maniar JK, Yoshihara N, Imai M, Kurimura T, Kitamura T (1993) Sequence analysis of V3 loop region of HIV-I strains prevalent in India. Jpn Med Sci Biol 46: 95-100
24. Hagler AT (1985) Theoretical simulation of conformation, energetics, and dynamics of peptides. In: Meienhofer J (ed) The peptides, vol 7. Academic Press, New York, pp 213-299
25. Hagler AT, Osguthorpe DJ, Dauber-Osguthorpe P, Hempel JC (1985) Dynamics and conformational energetics of a peptide hormone: vasopressin. Science 227: 1309-1315
26. Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT (1988) Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase trimethoprim, a drug-receptor system. Proteins Struct Fund Genet 4: 31-47
27. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI (1996) Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci USA 93: 3099-3104
28. Rein A, McClure M, Rice N, Luffing R, Schultz A (1986) Myristoylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc Natl Acad Sci USA 83: 7 246-7 250
29. Gottlinger H, Sodrosky J, Haseltine W (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86: 5781-5785
30. Bukrinsky M, Haggetry S, Dempsey M, Sharova N, Adzhubei A, Spitz L, Lewis P, Goldfarb D, Emerson M, Stevenson M (1993) A nuclear localization signal within matrix protein that governs infection of non-dividing cells. Nature 365: 666-669
31. Karrageorgos L, Li P, Burrell C (1993) Characterization of HIV replication complex early after cell-to cell infection. AIDS Res Hum Retroviruses 9: 817-827
32. Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, Sundquist WI (1994) Three-dimensional structure of the human immunodeficiency virus type I matrix protein. J Mol Biol 244: 198-223
33. Cannon PM, Matthews S, Clark N, Byles E, Lourin O, Hockley DJ, Kingsman SM, Kingsman AJ (1997) Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J Virol 71: 3474-3483
34. Soto-Ramirez LE, Renjifo B, McLane MF, Marlink R, O'Hara C, Sutthent R, Wasi C, Vithayasai P, Vthayasai V, Apichartpiyakul C, Aucwarakul P, Pena-Cruz. V, Chui D-S, Osathanondh R, Mayer K, Lee T-H, Essex M (1996) HIV-I Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 271: 1291-1 293
35. Naylor PH, Sztein MB, Wada S, Maurer S, Holterman D, Kirkely JE, Naylor CW, Zood BC, Hitzelberg RA, Gibbs CJ, Zagury D, Achour A. O'Toole C, Gazzard B, Youle M, Rios A, Sarin PS, Goldstein AL (1991) Preclinical and clinical studies on immunogenicity and safety of the HIV-1pl7-based synthetic peptide AIDS vaccinc-HGP-30/KLH. Int J Immunopharmc 13 [Suppl 1 ]: 117-127
36. Wilier A, Achour A, Mbika JP, Laaroubi K, Lachgar A, Nihrane A, Picard O, Naylor PH, Sarin PS, Goldstein AL, Zagury D (1992) Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus. Biomed Pharmacother 46: 359-365